France routes university technology transfer through a network of regional companies known as SATTs, according to an analysis published by CASRAI. The model is unusual in Europe: instead of each university running its own licensing office, a single legal entity per region holds, patents and licenses inventions on behalf of multiple public research institutions.

For R&D managers, the practical consequence is simple. A single negotiation counterpart covers a region's academic portfolio. For university researchers, the consequence is equally concrete: disclosure, maturation funding and licensing decisions sit with an external company, not with the laboratory's home institution.

What is a SATT?

A SATT (Société d'Accélération du Transfert de Technologie, a technology transfer acceleration company) is a private legal vehicle whose shareholders are the public research organisations and universities in its territory. Its mandate is to identify inventions disclosed by researchers, invest in their maturation — the stage between a validated lab result and a demonstrable prototype — and then license or spin out the technology.

The CASRAI piece frames the network as a centralisation play. Rather than dozens of under-resourced technology transfer offices operating at the scale of a single campus, each SATT aggregates deal flow across a whole region. In portfolio terms, that pools risk: one weak licensing year at a small university does not sink the regional vehicle, because the SATT draws on the combined invention stream of every partner institution.

How does the mechanism work?

The workflow, as the analysis describes it, has three stages.

• Invention disclosure. Researchers at partner institutions report potentially protectable results to the SATT rather than to a local office.
• Maturation. The SATT funds the work needed to make a result licensable — proof of concept, prototype development, regulatory positioning — using its central budget rather than departmental funds.
• Commercialisation. The SATT negotiates licences and spinout agreements on behalf of the originating institution, with returns flowing back through its shareholder structure.

The centralisation argument rests on scale. A regional company sees more inventions per year than any single campus office, which means more licensing experience per deal, a thicker network of industrial contacts and a larger internal budget for the expensive maturation phase. The comparison is straightforward: a campus office handles a trickle; a SATT handles a basin.

What should buyers and partners interrogate?

The CASRAI analysis presents the model on its own terms, and the claims deserve the same scrutiny any institutional self-description deserves. Points an R&D manager should test before treating a SATT as a reliable pipeline partner:

• Portfolio breadth versus depth. Aggregation increases deal count, but it does not guarantee sector expertise in the buyer's specific field.
• Maturation criteria. The company, not the originating laboratory, decides which disclosures receive funding. Partners should ask how those decisions are made and who sits on the investment committee.
• Terms standardisation. A single counterpart can standardise licence terms across institutions, which cuts transaction costs — but it can also reduce the flexibility to negotiate bespoke arrangements that a bilateral university deal might allow.

None of these points undermines the model. They define the diligence questions that any centralised transfer vehicle raises, in France or elsewhere.

Does centralisation change behaviour?

The structural claim in the analysis is that centralisation changes incentives. When transfer staff work at campus scale, their performance is judged on a thin stream of inventions; when they work at regional scale, professionalisation follows naturally, because the volume of deals justifies specialist staff in patenting, contracting and market analysis.

For university administrators, the model also answers a governance question. Public institutions in many countries struggle to justify the fixed cost of a transfer office against irregular licensing income. Moving that function into a shared company converts a fixed institutional cost into a shared equity position — the universities own the transfer vehicle rather than employing it.

What comes next?

CASRAI presents the SATT network as an established answer to a question every public research system faces: how to move inventions from laboratory to market without pricing small institutions out of professional transfer support. The network's next test, and the figure R&D managers should watch, is whether its regional licensing returns justify the maturation budgets it commits upstream.